Home › Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
 

Keywords :   


Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

2014-09-17 15:31:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for type data japanese

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.06Atlantic Tropical Weather Outlook
23.06Eastern North Pacific Tropical Weather Outlook
22.06AI and agriculture: A look at whats ahead
22.06Atlantic Tropical Weather Outlook
22.06Atlantic Tropical Weather Outlook
22.06Eastern North Pacific Tropical Weather Outlook
22.06This Week in Agribusiness, June 22, 2024
22.06This Week in Agribusiness, June 22, 2024
More »